| Literature DB >> 19884679 |
Wenli Yu1, Maria Serrano, Symone San Miguel, L Bruno Ruest, Kathy K H Svoboda.
Abstract
The development of the head involves the interaction of several cell populations and coordination of cell signalling pathways, which when disrupted can cause defects such as facial clefts. This review concentrates on genetic contributions to facial clefts with and without cleft palate (CP). An overview of early palatal development with emphasis on muscle and bone development is blended with the effects of environmental insults and known genetic mutations that impact human palatal development. An extensive table of known genes in syndromic and non-syndromic CP, with or without cleft lip (CL), is provided. We have also included some genes that have been identified in environmental risk factors for CP/L. We include primary and review references on this topic.Entities:
Year: 2009 PMID: 19884679 PMCID: PMC2825058 DOI: 10.4103/0970-0358.57185
Source DB: PubMed Journal: Indian J Plast Surg ISSN: 0970-0358
Syndromic genes associated with cleft lip and palate
| Apert Syndrome (AS) | AD; high arched palate, bifid uvula, and cleft palate. | FGFR2 | 6, 114–118 |
| Bamforth-Lazarus | AR; hypothyroidism, athyroidal, CPO, choanal atresia, spiky hair. | FOXE1 | 6, 119, 120 |
| Syndrome (BLS) | |||
| Branchio-oculo facial syndrome (BOFS) | AD; pseudocleft of the upper lip resembling a poorly repaired cleft lip. | TFAP2A | 6, 121 |
| Down syndrome (DS) | Macroglossia, microstomia, atlantoaxial subluxation | duplication of portion of chromosome 21 | 122 |
| Ectrodactyly-ectodermal dysplasia-cleft syndrome (EEC) | AD; triad of ectrodactyly, ectodermal dysplasia, and facial clefting. | P63 | 6, 123, 124 |
| Fetal alcohol syndrome (FAS) | Disorder characterized by a pattern of minor facial anomalies, prenatal and postnatal growth retardation. | alcohol dehydrogenase 1B (ADH1B) | 125-128 |
| Goldenhar syndrome (GS) | Oculo auricular vertebral dysplasia; AD; incomplete development of the ear, nose, soft palate, lip, mandible. | Pericentric inversion of chromosome 9 | 129, 130 |
| Hereditary lymphoedema-distichiasis syndrome (HLD) | AD; lymphedema of the limbs, double rows of eyelashes, cardiac defects, and cleft palate. | FOXC mutations | 131 |
| Kallmann Syndrome (KS) | AR disorder; hypogonadotropic hypogonadism and anosmia | FGFR1 mutations | 6, 132, 133 |
| Margarita Island ectodermal dysplasia (ED4) | AR; unusual facies, dental anomalies, syndactyly, and cleft lip/cleft palate. | PVRL1 (nectin-1) mutation | 6, 134 |
| Pierre Robin | AD; triad of micrognathia, glossoptosis, and cleft palate. | Loci 2q24.1-33.3, 4q32qter, 11q2123.1, and 17q2124.325.1. | 135,136 |
| Sequence (PRS) | |||
| Smith–Lemli-Opitz | AR; defects in cholesterol biosynthesis, growth retardation, dysmorphic facial features including CLP/ CPO, postaxial polydactyly | DHCR | 6, 137, 138 |
| Syndrome (SLMOS) | |||
| Stickler Syndrome (SS) | |||
| AD; midface hypoplasia, micrognathia, Pierre Robin sequence, retinal detachment and early cataracts deafness, hypermobility of joints. | Col11A1, Col11A2, Col2A1 | 139,140 | |
| Treacher Collins (TC) | AD; craniofacial deformities such as downward slanting eyes, micrognathia, conductive hearing loss, underdeveloped zygoma. | Mutation in TCOF1 gene at chromosome 5q32-q33.1 | 141, 142 |
| van der Woude syndrome (VDWS) | AD; cleft lip palate, distinctive pits of the lower lips, or both. | IRF 6 (interferon regulatory factor 6) mutations | 6, 143 |
| Velocardiofacial | AD; cleft palate, heart defects, abnormal facial structure, and learning problems. | Chromosome 22q11 microdeletion | 144, 145 |
| Syndrome (VCFS) | |||
| Unnamed syndrome | CL/P and hereditary diffuse gastric cancer | CDH1 | 72 |
| Unnamed syndrome | Chromodomain helicase DNA-binding proteins; CL/P in Charge syndrome | CHD7 | 146, 147 |
| Unnamed syndrome | Bilateral CL/P, colobomas of the optic nerve and retina, agenesis of the corpus callosum. Dysphagia, reduced Oesophgeal peristalsis | PAX 9 | 6, 148 |
| Unnamed syndrome | X-linked mental retardation and CL/P | PH8 | 6, 149 |
| Unnamed syndrome | Holoprosencephaly 7, a spectrum of forebrain and midline anomalies and midline CL | PTCH | 6, 137, 150, 151 |
| Unnamed syndrome | CPO, craniofacial anomalies, osteoporosis, and cognitive defects | SATB2 | 6, 152 |
| Unnamed syndrome | Holoprosencephaly, a spectrum of anomalies ranging from severe (cyclopia) to subtle midline asymmetries. CL/P part of the spectrum | SHH | 6, 137 |
| Unnamed syndrome | Anomalies with most features of DiGeorge/velocardiofacial syndromes: CPO, thymus and parathyroid gland hypoplasia, vertebra, facial and cardiac outflow anomalies. | TBX1 | 6, 153 |
| Unnamed syndrome | X-linked CPO and ankyloglossia | TBX22 | 6, 51, 52 |
| Unnamed syndrome | Cardiovascular, craniofacial, skeletal, and cognitive alterations, bifid uvula and or/CPO | TGF Beta receptor | 6, 154 |
Non-syndromic genes: interaction effects of genes and environmental risk factors on oral clefts
| Cytochrome P450 Proteins (CYP) CYPIA1, CYPIA2, CYPIB1 CYP2E1 | Highly polymorphic, having multiple functional alleles; Role in detoxification; metabolism of endogenous morphogens in the developing foetus. | Negative gene-smoking interaction effect | 155-157 |
| Epoxide Hydrolase (EPHX) | Class of proteins that catalyze the hydration of chemically reactive epoxides into their corresponding dihydrodiol products. | ||
| EPHX | Plays an important role in both the bioactivation and detoxification of exogenous chemicals such as PAHs, which are present in cigarette smoke. | Negative gene-smoking interaction effect | 155, 158 |
| EPHX1 Y113H | Variant of EPHX 1 found in the foetus and maternal smoking. | Positive gene-smoking interaction effect | 28, 159 |
| Glutathione Transferase Gene Family (GST) | Families of dimeric phase II enzymes that catalyze the conjugation of reduced glutathione with electrophilic groups of a wide variety of environmental agents. | ||
| GSTM1 | Major gene detoxifying PAHs and widely studied in many disorders and cancers. | Negative gene-smoking interaction effect | 160, 161 |
| GSTT1 | Expressed in a variety of tissues/organs such as erythrocytes, lung, kidney, brain, skeletal muscles, heart, and small intestine; elevated expression profile at the craniofacial regions during embryonic development. | Positive gene-smoking interaction effect | 162, 28, 157, 159 |
| GSTP1 | Major gene detoxifying PAHS; involvement in variety of disorders and cancers. Major enzyme involved in the inactivation of cigarette smoker's metabolites; most important isoform at the embryonic and early foetal developmental stages. | Positive gene-smoking interaction effect | 163, 28, 159 |
| GST A4 / GSTM3 | Two other types of GST gene family members. | Positive gene-smoking interaction effect | 28, 159 |
| Hypoxia-Induced Factor-1 (HIF1A) | Mechanism by which maternal smoking may affect embryonic development due to the production of carbon monoxide, which interferes with oxygen transfer to the placenta, or nicotine, which constricts the uterine wall resulting in hypoxia. | Positive gene-smoking interaction effect | 28, 159 |
| Arylamine N-Acetyltransferase gene Family | N-conjugation of arylamine by the action of N-acetyltransferases (NATs), UDP glucoronosyltransferases (UGTs), or sulfotransferases (SULTS) produces nontoxic compounds. | ||
| N-acetyltransferases1 (NAT 1) | Expressed in many tissues such as erythrocytes, bladder, lymphocytes, neural tissues, liver and intestines. | Negative gene-smoking interaction effect | 19, 164, 165 |
| N-acetyltransferases pseudogene, (NATP1) | Pseudogene identified, which is located at chromosome 8p23.1-8p21.3. | 19, 164, 165 | |
| N-acetyltransferases2 (NAT 2) | Expressed in the liver and epithelial cells of the intestine. | Positive gene-smoking interaction effect | 28, 157, 159 |
| Methylenetetrahydrofolate reductase (MTHFR) | Metabolism of folate by reducing methylenetrahydrofolate, primary donor for methionine synthesis. | Positive gene-smoking interaction effect | 166-172 |
| MTHFRC677T | Variant of methylenetetrahydrofolate reductase. | Negative gene-smoking interaction effect | |
| OTHER METABOLIC GENES | |||
| NAD(P)H quinine oxidoreductase (NQO1) | Flavoenzyme that catalyzes two electron reduction of quinine compounds to hydroquinone and is inducible by oxidative stress, dioxin, and PAHS found in cigarette smoke | Negative gene-smoking interaction effect | 28, 159 |
| SULT1A1 | Catalyzes transfer of the sulfonate group from the active sulfate to a substrate to form the respective sulfate or sulfamate ester. | Negative gene-smoking interaction effect | 28, 159 |
| UDP glycosyltransferases (UGTs) UGT1A7 variant | Catalyzes conjugation reactions where hydrophobic chemicals are transformed into water-soluble compounds. Potential maternal effects on embryonic development. | Positive gene-smoking interaction effect | 159, 173, 174 |
| DEVELOPMENTAL GENES FOR ORAL CLEFTS | |||
| Transforming Growth Factor A (TGF α) | Transmembrane protein expressed at the medial edge of the epithelium (MEE) of fusing palatal shelves. Its receptor epidermal growth factor (EGFR) is expressed in the degenerating MEE. | Positive gene-smoking interaction effect (smoking, alcohol drinking, vitamins) | 175-177 |
| Transforming growth Factor β-3 (TGF β3) | Regulator of many biological processes such as proliferation, differentiation, epithelial mesenchymal transformation and apoptosis. | Positive gene-smoking interaction effect (smoking, alcohol drinking) | 81, 176, 178 |
| Muscle Segment Homeobox1 (MSX1) | Transcriptional repressor important in craniofacial, limb, and nervous system development. | Positive gene-smoking interaction effect (smoking and alcohol drinking) | 176, 179, 180 |
| MSX2 | Similar to MSX1; rare cause of isolated cleft lip with or without cleft palate. | 179, 180 | |
| Acyl-CoA desaturase ACOD4 | Pericentric inversion disrupts a gene (ACOD4) on chromosome 4q21 that codes for a novel acyl-CoA desaturase enzyme that occurs in a single two-generation family with CL. | 181 | |
| Retinoic acid receptor (RAR) | Odds ratios for transmission of alleles at THRA1 were significant when ethnic group was included. | Negative gene-smoking interaction effect | 176 |
| CHD7 | Chromodomain helicase DNA-binding proteins. | 182 | |
| ESR1 | Ligand-activated TF estrogen receptor. | 183 | |
| FGF/ FGFR families FGF8 FGF3 FGF10 FGF18 FGFR1 FGFR2 FGFR3 | Expressed during craniofacial development and can rarely harbor mutations that result in human clefting syndromes. | 184 | |
| SPRY1/SPRY2 | Loss of function mutations in FGFR1 cause a syndromic form of clefting. | 185 | |
| TBX10 | Ectopically expressed in dancer cleft lip and palate mutant mice. | 185 | |
| GABRB3 | β3 subunit of GABA receptor CL/P. | 62, 186, 6 | |
| GLI2 | Mutations in GLi2 cause holoprosencephaly-like features with cleft lip and palate. | 185 | |
| ISGF3G | Similar to IRF6. | 185 | |
| OTHER CANDIDATE GENES | |||
| SKI, FOXE1, JAG2, LHX8 | Rare causes of isolated cleft lip with or without cleft palate | 185 | |
Figure 1Schematic drawing showing coronal view of a normal palate shelf and key stages of mouse palatal development. At E12-E13 days in the mouse gestation, the palatal shelves grow downward along the tongue (t). At E13-E13.5 days, the palatal shelves become elevated above the tongue. At E14.5, the palatal shelves adhere to each other in the midline. After E15.5 days, the MES completely degrades, and the palate fuses
Figure 2Comparison of the morphogenesis of the upper lip (A-C) with that of the palate (D-F). After the bilateral maxillary processes (max) fuse externally with the inter-maxillary segment, the resulting epithelial seam (arrow, B) gives rise to mesenchyme (arrowhead, C) to produce a confluent lip. At a later time, the palatal shelves arising internally from the maxillary processes fuse with each other (arrows, D) and with the nasal septum (ns) above them, creating an epithelial seam that transforms to mesenchyme (arrowheads, E) to produce the confluent palate (arrowheads, F). p, sloughed periderm cells. Reprinted with permission.[44]
Figure 3(A) Diagram showing the relationship between the NC cartilages and the transpalatal suture. Dotted lines indicate cut lines for removing the palate from the embryo and the NC cartilage from above the sutures. (B-E) Micrographs of parasagittal sections of foetal rat heads show the pre-natal development of TP sutures. (B) At E16, NC cartilages (arrows) can be seen directly above the presumptive TP suture region (in box). (C) High-power micrograph of the region in the box, showing the advancing palatal plate of the maxilla and horizontal plate of the palatal bone (asterisks) on either side of the presumptive TP suture (between arrows). (D) At E18, the advancing bone fronts (asterisks) begin to overlap one another, creating a highly cellular suture blastema (between arrows). (E) By E20, an elongated TP suture (between arrows) continues to form as the bone fronts proceed to overlap one another. A, airway; B, shelves of maxillary bones; MP, midpalatal suture; NCC, nasal capsular cartilage; O, oral cavity; TP, transpalatal suture. Reprinted with permission.[87]